Risdiplam is a potential rival to Biogen’s Spinraza (nusinersen), a spinally injected antisense drug that tells the body to produce the SMN protein that is defective in patients with SMA and has ...

Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful ...

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision due by 24 May next year. If approved, risdiplam will be the third drug to be ...

So far, the child's lack of symptoms comes as a successful result of the orally administered drug risdiplam, developed by ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

He had a hunch that the oral SMA treatment risdiplam, made by Roche, had prenatal potential because it’s safe for kids and ...

Natco revealed in a “legal update regarding Risdiplam launch in India” that the “company has decided to price the product (Risdiplam) at Rs 15,900” per 60 mg bottle. An individual with a ...